Use of the Decipher genomic classifier among men with prostate cancer in the United States.

ABSTRACT:

Background

Management of localized or recurrent prostate cancer since the 1990s has been based on risk stratification using clinicopathological variables, including Gleason score, T stage (based on digital rectal exam), and prostate-specific antigen (PSA). In this study a novel prognostic test, the Decipher Prostate Genomic Classifier (GC), was used to stratify risk of prostate cancer progression in a US national database of men with prostate cancer.

Methods

Records of prostate cancer cases from participating SEER (Surveillance, Epidemiology, and End Results) program registries, diagnosed during the period from 2010 through 2018, were linked to records of testing with the GC prognostic test. Multivariable analysis was used to quantify the association between GC scores or ris

SUBMITTER: Zaorsky NG 

PROVIDER: S-EPMC10505256 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature